Boronate-Based Bioactive Compounds Activated by Peroxynitrite and Hydrogen Peroxide

Overview

Journal Redox Biochem Chem

Specialty Biochemistry

Date 2024 Dec 16

PMID 39678628

Authors

Monika Rola

Jacek Zielonka

Renata Smulik-Izydorczyk

Jakub Pieta

Karolina Pierzchala

Adam Sikora

Radoslaw Michalski

Affiliations

Soon will be listed here.

Abstract

Boronates react directly and stoichiometrically with peroxynitrite and hydrogen peroxide. For this reason, boronates have been widely used as peroxynitrite- and hydrogen peroxide-sensitive moieties in various donors of bioactive compounds. So far, numerous boronate-based prodrugs and theranostics have been developed, characterized, and used in biological research. Here, the kinetic aspects of their activation are discussed, and the potential benefits of modifying their original structure with a boronic or boronobenzyl moiety are described.

References

Bhagat S, Singh U, Mishra R, Srivastava A . An Endogenous Reactive Oxygen Species (ROS)-Activated Histone Deacetylase Inhibitor Prodrug for Cancer Chemotherapy. ChemMedChem. 2018; 13(19):2073-2079. DOI: 10.1002/cmdc.201800367. View

Maslah H, Skarbek C, Pethe S, Labruere R . Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment. Eur J Med Chem. 2020; 207:112670. DOI: 10.1016/j.ejmech.2020.112670. View

Debowska K, Debski D, Michalowski B, Dybala-Defratyka A, Wojcik T, Michalski R . Characterization of Fluorescein-Based Monoboronate Probe and Its Application to the Detection of Peroxynitrite in Endothelial Cells Treated with Doxorubicin. Chem Res Toxicol. 2016; 29(5):735-46. DOI: 10.1021/acs.chemrestox.5b00431. View

Takagi R, Takeda A, Takahashi D, Toshima K . Target-Selective Fluorescence Imaging and Photocytotoxicity against H O High-Expressing Cancer Cells Using a Photoactivatable Theranostic Agent. Chem Asian J. 2017; 12(20):2656-2659. DOI: 10.1002/asia.201701004. View

Liu H, Hu X, Li K, Liu Y, Rong Q, Zhu L . A mitochondrial-targeted prodrug for NIR imaging guided and synergetic NIR photodynamic-chemo cancer therapy. Chem Sci. 2018; 8(11):7689-7695. PMC: 5861986. DOI: 10.1039/c7sc03454g. View

Odyniec M, Han H, Gardiner J, Sedgwick A, He X, Bull S . Peroxynitrite Activated Drug Conjugate Systems Based on a Coumarin Scaffold Toward the Application of Theranostics. Front Chem. 2019; 7:775. PMC: 6906548. DOI: 10.3389/fchem.2019.00775. View

Maslah H, Skarbek C, Gourson C, Plamont M, Pethe S, Jullien L . In-Cell Generation of Anticancer Phenanthridine Through Bioorthogonal Cyclization in Antitumor Prodrug Development. Angew Chem Int Ed Engl. 2021; 60(45):24043-24047. DOI: 10.1002/anie.202110041. View

Wei Y, Guo M . Hydrogen peroxide triggered prochelator activation, subsequent metal chelation, and attenuation of the fenton reaction. Angew Chem Int Ed Engl. 2007; 46(25):4722-5. PMC: 2754069. DOI: 10.1002/anie.200604859. View

Zhang C, Zhong Q, Zhang Q, Zheng S, Miele L, Wang G . Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer. Breast Cancer Res Treat. 2015; 152(2):283-91. PMC: 4524496. DOI: 10.1007/s10549-015-3461-9. View

10.

Szabo C, Ischiropoulos H, Radi R . Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov. 2007; 6(8):662-80. DOI: 10.1038/nrd2222. View

11.

Lee D, Park S, Bae S, Jeong D, Park M, Kang C . Hydrogen peroxide-activatable antioxidant prodrug as a targeted therapeutic agent for ischemia-reperfusion injury. Sci Rep. 2015; 5:16592. PMC: 4643254. DOI: 10.1038/srep16592. View

12.

Engel M, Gee Y, Cross D, Maccarone A, Heng B, Hulme A . Novel dual-action prodrug triggers apoptosis in glioblastoma cells by releasing a glutathione quencher and lysine-specific histone demethylase 1A inhibitor. J Neurochem. 2018; 149(4):535-550. PMC: 6590141. DOI: 10.1111/jnc.14655. View

13.

Jia Z, Zhu H, Li Y, Misra H . Potent inhibition of peroxynitrite-induced DNA strand breakage and hydroxyl radical formation by dimethyl sulfoxide at very low concentrations. Exp Biol Med (Maywood). 2010; 235(5):614-22. DOI: 10.1258/ebm.2010.009368. View

14.

Reshetnikov V, Daum S, Janko C, Karawacka W, Tietze R, Alexiou C . ROS-Responsive N-Alkylaminoferrocenes for Cancer-Cell-Specific Targeting of Mitochondria. Angew Chem Int Ed Engl. 2018; 57(37):11943-11946. DOI: 10.1002/anie.201805955. View

15.

Jansova H, Machacek M, Wang Q, Haskova P, Jirkovska A, Potuckova E . Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. Free Radic Biol Med. 2014; 74:210-21. PMC: 4243170. DOI: 10.1016/j.freeradbiomed.2014.06.019. View

16.

Kumar R, Han J, Lim H, Ren W, Lim J, Kim J . Mitochondrial induced and self-monitored intrinsic apoptosis by antitumor theranostic prodrug: in vivo imaging and precise cancer treatment. J Am Chem Soc. 2014; 136(51):17836-43. DOI: 10.1021/ja510421q. View

17.

Kielar F, Wang Q, Boyle P, Franz K . A boronate prochelator built on a triazole framework for peroxide-triggered tridentate metal binding. Inorganica Chim Acta. 2013; 393:294-303. PMC: 3579658. DOI: 10.1016/j.ica.2012.06.011. View

18.

Manikandan P, Nagini S . Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr Drug Targets. 2017; 19(1):38-54. DOI: 10.2174/1389450118666170125144557. View

19.

Zhang Y, Yang J, Meng T, Qin Y, Li T, Fu J . Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents. Eur J Med Chem. 2021; 212:113153. DOI: 10.1016/j.ejmech.2021.113153. View

20.

Wang R, Chen H, Yan W, Zheng M, Zhang T, Zhang Y . Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships. Eur J Med Chem. 2020; 190:112109. DOI: 10.1016/j.ejmech.2020.112109. View